TGA Internet site archive
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Cost recovery impact statements (archived consultations & reviews)
2016-2017
- Cost recovery implementation statement 2016-17
This CRIS provides information on how the Therapeutic Goods Administration (TGA) implements cost recovery of regulatory activities.
2015-2016
- Cost recovery implementation statement: Blood, blood components and biologicals (human cell and tissue therapies), From 1 July 2015
Information on cost recovery of activities associated with the inclusion of biologicals (human cell and tissue therapies) onto the ARTG and the regulation of blood, blood components and biologicals through inspection and licensing of manufacturers - Cost recovery implementation statement: Complementary medicines , From 1 July 2015
Information on cost recovery of activities associated with the registration or listing of complementary medicines onto the ARTG and the ongoing monitoring and surveillance - Cost recovery implementation statement: Good manufacturing practice, From 1 July 2015
Information on cost recovery of activities associated with the manufacture of medicines - Cost recovery implementation statement: Medical devices, From 1 July 2015
Information on cost recovery of activities associated with the inclusion of medical devices, including in vitro diagnostic (IVD) devices, onto the ARTG and the ongoing monitoring and surveillance - Cost recovery implementation statement: Over the counter medicines, From 1 July 2015
information on cost recovery of activities associated with the registration or listing of OTC medicines onto the ARTG and the ongoing monitoring and surveillance - Cost recovery implementation statement: Prescription medicines, From 1 July 2015
Information on cost recovery of activities associated with the registration of prescription medicines onto the ARTG and the ongoing monitoring and surveillance
2014-2015
- Cost recovery impact statement: Blood, blood components and biologicals (human cell and tissue therapies), 1 July 2014 - 30 June 2015
Information on cost recovery of activities associated with the inclusion of biologicals (human cell and tissue therapies) onto the ARTG and the regulation of blood, blood components and biologicals through inspection and licensing of manufacturers - Cost recovery impact statement: Complementary medicines, 1 July 2014 - 30 June 2015
Information on cost recovery of activities associated with the registration or listing of complementary medicines onto the ARTG and the ongoing monitoring and surveillance - Cost recovery impact statement: Good manufacturing practice, 1 July 2014 - 30 June 2015
Information on cost recovery of activities associated with the manufacture of medicines - Cost recovery impact statement: Medical devices, 1 July 2014 - 30 June 2015
Information on cost recovery of activities associated with the inclusion of medical devices, including in vitro diagnostic (IVD) devices, onto the ARTG and the ongoing monitoring and surveillance - Cost recovery impact statement: Over the counter medicines, 1 July 2014 - 30 June 2015
information on cost recovery of activities associated with the registration or listing of OTC medicines onto the ARTG and the ongoing monitoring and surveillance - Cost recovery impact statement: Prescription medicines, 1 July 2014 - 30 June 2015
Information on cost recovery of activities associated with the registration of prescription medicines onto the ARTG and the ongoing monitoring and surveillance
2013-2014
- Cost recovery impact statement - Blood, tissues and human cell and tissue therapies, 1 July 2013 - 30 June 2014
- Cost recovery impact statement - Complementary medicines, 1 July 2013 - 30 June 2014
- Cost recovery impact statement - Good manufacturing practice, 1 July 2013 - 30 June 2014
- Cost recovery impact statement - Medical devices, 1 July 2013 - 30 June 2014
- Cost recovery impact statement - Over the counter medicines, 1 July 2013 - 30 June 2014
- Cost recovery impact statement - Prescription medicines, 1 July 2013 - 30 June 2014
2012-2013
- Cost recovery impact statement - Good manufacturing practice, 1 July 2012 - 30 June 2013
- Cost recovery impact statement - Medical devices, 1 July 2012 - 30 June 2013
- Addendum to cost recovery impact statements, 1 July 2012 - 30 June 2013
2010-2011
2009-2010
- Regulation of in-vitro diagnostic devices (IVDs)
- Annual review of fees and charges 2009-10 - Prescription medicines
- Annual review of fees and charges 2009-10 - Non-prescription medicines
- Annual review of fees and charges 2009-10 - Complementary medicines
- Annual review of fees and charges 2009-10 - Blood, blood components and human tissues
- Draft cost recovery impact statements (annual review of fees and charges 2009-10)
2008 & earlier
- Annual review of fees and charges 2008-09 - Non prescription (registered) medicines
- Annual review of fees and charges 2006-07 - Non prescription (registered and listed) medicines
- Regulation of in-vitro diagnostic devices
- Report on cost recovery arrangements relating to the regulation of the medicines, medical devices and blood products by the Therapeutic Goods Administration